Pure Global AI
NCT06404697Recruiting

Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients

Evaluating the Efficacy and Safety of Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients According to Nodal Response: a Single-arm, Prospective Clinical Study
Ruijin HospitalPhase 2ClinicalTrials.govradiation
Verified
Study focus
Disease/Condition
Breast Cancer
Drug/Device/Intervention
Boost irradiation
Study type
Interventional
Intervention type
radiation
Sponsor & location
Primary sponsor
Ruijin Hospital
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2024
End date
Apr 01, 2030
Enrollment
24 participants
Primary outcome

2-year recurrence-free survival

Summary

cN3c breast cancer with ipsilateral supraclavicular (SCV) lymph nodal (SCLN) metastasis is
 known to have a dismal prognosis. Currently, the combined-modality therapy consisting of
 primary systemic therapy (PST), subsequent local and/or systemic therapy based on response is
 the standard of care. However, the value of giving radiotherapy (RT) boost to SCV region
 remains uncertain in cN3c patients. This study aimed to assess the efficacy and safety of RT
 boost to the SCV area in high-risk cN3c breast cancer patients based on nodal response
 following PST.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedMalignant neoplasm: Breast, unspecifiedOther carcinoma in situ of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06404697
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06404697 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ruijin Hospital and is currently Recruiting. The study focuses on Breast Cancer. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.